Inovio Pharmaceuticals, Inc.

Equities

INO

US45773H4092

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-26 pm EDT			5-day change	1st Jan Change
10.57 ^USD	+4.40%		+9.19%	+72.71%

Apr. 16	Powell Comments, Middle East Tensions in Focus as US Equity Futures Gain Pre-Bell	MT
Apr. 16	Inovio Pharmaceuticals Shares Slump Pre-Bell After Pricing of $36 Million Offering of Common Stock, Warrants	MT

Inovio Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023

November 09, 2023 at 04:00 pm EST

Inovio Pharmaceuticals, Inc. reported earnings results for the third quarter and nine months ended September 30, 2023. For the third quarter, the company reported net loss was USD 33.93 million compared to USD 37.78 million a year ago. Basic loss per share from continuing operations was USD 1.56 compared to USD 1.8 a year ago.
For the nine months, net loss was USD 110.11 million compared to USD 225.35 million a year ago. Basic loss per share from continuing operations was USD 5.04 compared to USD 11.52 a year ago.

Latest news about Inovio Pharmaceuticals, Inc.

Powell Comments, Middle East Tensions in Focus as US Equity Futures Gain Pre-Bell	Apr. 16	MT
Inovio Pharmaceuticals Shares Slump Pre-Bell After Pricing of $36 Million Offering of Common Stock, Warrants	Apr. 16	MT
Top Premarket Decliners	Apr. 16	MT
Transcript : Inovio Pharmaceuticals, Inc., Q4 2023 Earnings Call, Mar 06, 2024	Mar. 06
Inovio Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 06	CI
Oppenheimer Upgrades Inovio Pharmaceuticals to Outperform From Perform, $4 Price Target	Jan. 25	MT
Transcript : Inovio Pharmaceuticals, Inc. - Special Call	Jan. 24
Inovio Pharmaceuticals, Coherus BioSciences to Collaborate on Potential Throat Cancer Treatment	Jan. 04	MT
INOVIO and Coherus Announces Clinical Collaboration to Advance Development of INO-3112 in Combination with LOQTORZI?? (toripalimab-Ttzi)	Jan. 04	CI
Inovio Pharmaceuticals Plans BLA Submission for INO-3107 for Recurrent Respiratory Papillomatosis Treatment	Jan. 03	MT
INOVIO Plans to Submit a BLA for INO-3107 as a Potential Treatment for RRP in Second Half of 2024 Under Accelerated Approval Program	Jan. 03	CI
Inovio Pharmaceuticals, Inc.(NasdaqCM:INO) dropped from NASDAQ Biotechnology Index	Dec. 15	CI
Transcript : Inovio Pharmaceuticals, Inc., Q3 2023 Earnings Call, Nov 09, 2023	Nov. 09
Inovio Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 09	CI
Inovio Shares Rise 8% After FDA Feedback for INO-3107	23-10-10	DJ
Inovio Pharmaceuticals Advised to File BLA for Drug Candidate to Treat Recurrent Respiratory Papillomatosis	23-10-10	MT
Inovio Pharmaceuticals, Inc. Receives FDA Feedback That Data from Completed Phase 1/2 Trial of INO-3107	23-10-10	CI
Inovio Says US FDA Breakthrough Therapy Designation Received for Recurrent Respiratory Papillomatosis Drug Candidate	23-09-07	MT
Transcript : Inovio Pharmaceuticals, Inc., Q2 2023 Earnings Call, Aug 09, 2023	23-08-09
Inovio Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-09	CI
Inovio Pharmaceuticals to Cut 30% of Full-Time Workforce	23-08-01	MT
Inovio Pharmaceuticals Plans to Cut About 30% of Workforce	23-08-01	MT
Inovio Pharmaceuticals, Inc.(NasdaqGS:INO) dropped from Russell Microcap Value Index	23-06-23	CI
Inovio Pharmaceuticals, Inc.(NasdaqGS:INO) dropped from Russell Small Cap Completeness Index	23-06-23	CI
Inovio Pharmaceuticals, Inc.(NasdaqGS:INO) dropped from Russell 2500 Index	23-06-23	CI

Chart Inovio Pharmaceuticals, Inc.

Duration

Period

More charts

Company Profile

Inovio Pharmaceuticals, Inc. is a clinical-stage biotechnology company. The Company is focused on developing and commercializing deoxyribonucleic acid (DNA) medicines to help treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines pipeline include INO-3107 for HPV-related recurrent respiratory papillomatosis (RRP); INO-3112 for the treatment of HPV-related Oropharyngeal Squamous Cell Carcinoma, or OPSCC; VGX-3100 for the treatment of Anal or Perianal HSIL; INO-5401 for the treatment of Glioblastoma Multiforme (GBM), and INO-5401 for the Treatment of Glioblastoma Multiforme (GBM). Its lead candidate is INO-3107 for the treatment of RRP, a rare and debilitating disease of the respiratory tract caused by HPV infection. Its DNA medicines platform consists of DNA plasmids and its CELLECTRA devices, which are used to deliver the DNA plasmids into the cell. Its CELLECTRA device portfolio consists of two models.

Sector

Biotechnology & Medical Research

Calendar

2024-05-07 - Q1 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for Inovio Pharmaceuticals, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

10.57 USD

Average target price

19.25 USD

Spread / Average Target

+82.12%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
INOVIO PHARMACEUTICALS, INC.	+72.71%	274M
IQVIA HOLDINGS INC.	+1.51%	42.75B
MODERNA, INC.	+8.57%	41.34B
LONZA GROUP AG	+49.22%	41.61B
CELLTRION, INC.	-12.36%	26.59B
ICON PUBLIC LIMITED COMPANY	+8.92%	25.49B
ALNYLAM PHARMACEUTICALS, INC.	-25.13%	18.12B
MEDPACE HOLDINGS, INC.	+29.17%	12.24B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-3.12%	11.76B
UNITED THERAPEUTICS CORPORATION	+6.35%	11B

Other Biotechnology & Medical Research